| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Koller), University of Miami, Miami, FL; Neurology Research and Education Center (Dr. Hutton), Lubbock, TX; Department of Neurology (Dr. Tolosa), Hospital Clinico Universitario, Barcelona, Spain; and Tulip Tree Cottage (Dr. Capilldeo), UK.
Address correspondence and reprint requests to Dr. William C. Koller, Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7314.
OBJECTIVE: To compare effects of immediate-release (IR) and sustained-release (CR) carbidopa/levodopa in levodopa-naive PD patients.
BACKGROUND: It was hypothesized that the long-acting preparation would be associated with fewer long-term complications.
METHODS: A total of 618 patients were studied in 36 centers worldwide in a blinded, randomized parallel study. Measures of efficacy and adverse reactions were recorded at 3-month intervals for 5 years. Motor fluctuations and dyskinesias were evaluated by a patient diary and a physician-recorded questionnaire. The Nottingham Health Profile (NHP) was used to evaluate quality of life.
RESULTS: Approximately 60% of patients completed the trial. After 5 years, the mean dose of IR was 426 mg/day, and the bioavailable dose of CR was 510 mg/day (mean dose, 736 mg/day). After 5 years, 20.6% of the IR group and 21.8% of the CR group had motor fluctuations or dyskinesia. Sixteen percent of both groups had changes in motor response by the questionnaire’s definition. There was no significant difference between the two treatment groups. Disability scores and the motor score of the Unified Parkinson Disease Rating Scale (UPDRS) were highest at baseline, improved with therapy, and thereafter worsened over time to reach baseline scoring at the end of 5 years. The CR group was superior to IR for the Activities of Daily Living subsection of the UPDRS for all 5 years and for emotional reactivity and social isolation on the NHP; however, this may have resulted from higher doses of CR that were used.
CONCLUSION: Despite the progressive nature of PD, both the immediate-release and sustained-release carbidopa/levodopa formulations maintained a similar level of control in PD after 5 years compared with baseline. Additionally, the low incidence of motor fluctuations or dyskinesia was not significantly different between the treatment groups and may be partly attributed to the relatively low doses of levodopa used throughout the 5-year study.
Key words: PD—Carbidopa/levodopa—Motor fluctuations—Dyskinesias.
This article has been cited by other articles:
|
|
 |
|
  P. A. LeWitt Levodopa for the Treatment of Parkinson's Disease N. Engl. J. Med., December 4, 2008; 359(23): 2468 - 2476. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Chen and R. Pahwa Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease Journal of Pharmacy Practice, August 1, 2008; 21(4): 244 - 253. [Abstract] [PDF]
|
|
|
|
|
|
J. G. Nutt and G. F. Wooten Diagnosis and Initial Management of Parkinson's Disease N. Engl. J. Med., September 8, 2005; 353(10): 1021 - 1027. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Stocchi, L. Vacca, S. Ruggieri, and C. W. Olanow Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease: A Clinical and Pharmacokinetic Study Arch Neurol, June 1, 2005; 62(6): 905 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Mouradian Should levodopa be infused into the duodenum? Neurology, January 25, 2005; 64(2): 182 - 183. [Full Text] [PDF]
|
|
|
|
|
|
C. W. Shults Treatments of Parkinson Disease: Circa 2003 Arch Neurol, December 1, 2003; 60(12): 1680 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barone Clinical strategies to prevent and delay motor complications Neurology, September 23, 2003; 61(90063): S12 - 16. [Abstract] [Full Text]
|
|
|
|
 |
|
 D J Brooks and H Sagar Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1071 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Marras and A E Lang Measuring motor complications in clinical trials for early Parkinson's disease J. Neurol. Neurosurg. Psychiatry, February 1, 2003; 74(2): 143 - 146. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Chappell and H. Cohen Frontiers in Neuropharmacotherapy Part II: Multiple Sclerosis and Parkinson's Disease Journal of Pharmacy Practice, June 1, 2002; 15(3): 221 - 240. [Abstract] [PDF]
|
|
|
|
|
|
C. G. Goetz and V. K. Hinson Therapies for Movement Disorders Arch Neurol, May 1, 2002; 59(5): 699 - 702. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Holloway and A. W. Dick Clinical trial end points: On the road to nowhere? Neurology, March 12, 2002; 58(5): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]
|
|
|
|
|
|
C. H. Adler Relevance of motor complications in Parkinson's disease Neurology, February 1, 2002; 58(90001): S51 - 56. [Abstract] [Full Text]
|
|
|
|
|
|
W. C. Koller Treatment of early Parkinson's disease Neurology, February 1, 2002; 58(90001): S79 - 86. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Miyasaki, W. Martin, O. Suchowersky, W. J. Weiner, and A. E. Lang Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, January 8, 2002; 58(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Marek, R. Innis, C. van Dyck, B. Fussell, M. Early;, S. Eberly, D. Oakes, and J. Seibyl [123I]{beta}-CIT SPECT imaging assessment of the rate of Parkinson's disease progression Neurology, December 11, 2001; 57(11): 2089 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]
|
|
|
|
|
|
J R PONSFORD and D J BROOKS Treatment of early onset Parkinson's disease with ropinirole J. Neurol. Neurosurg. Psychiatry, March 1, 2001; 70(3): 418 - 419. [Full Text]
|
|
|
|
|
|
G. Van Horn, M. C. Schiess, and W. C. Koller Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study Neurology, July 12, 2000; 55(1): 156 - 157. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Hutton, E. S. Tolosa, R. Capildeo, and J. L. Morris Levodopa-Treated Parkinson Disease Has Better Long-term Outcome Than Previously Predicted Arch Neurol, May 1, 2000; 57(5): 758 - 759. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
